Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

These Analysts Increase Their Forecasts On Procter & Gamble After Strong Q3 Earnings

Procter & Gamble Co (NYSE: PG) reported better-than-expected earnings for its third quarter on Wednesday.
byLisa Levin
October 19, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Procter & Gamble Co (NYSE:PG) reported better-than-expected earnings for its third quarter on Wednesday.

Procter & Gamble reported first-quarter FY24 sales growth of 6.1% year-over-year to $21.87 billion, beating the consensus of $21.67 billion. Adjusted EPS of $1.83 (+17% Y/Y) beat the consensus of $1.71.

Procter & Gamble shares fell 0.4% to trade at $148.48 on Thursday.

These analysts made changes to their price targets on Procter & Gamble following earnings announcement.

  • Stifel raised the price target on Procter & Gamble from $151 to $155. Stifel analyst Mark Astrachan maintained a Hold rating.
  • Wells Fargo increased the price target on Procter & Gamble from $160 to $162. Wells Fargo analyst Chris Carey maintained an Overweight rating.

Also Check This Out: Top 3 Financial Stocks You’ll Regret Missing In Q4

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Recap: AT&T Q3 Earnings

By Benzinga Insights
October 20, 6:51 AM
AT&T (NYSE:T) reported its Q3 earnings results on Thursday, October 20, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings AT&T beat estimated earnings by 11.48%, reporting an EPS of $0.68 versus an estimate of $0.61.

T

Read More

Athersys Reports Interim Analysis Results Of MASTERS-2 Clinical Study With MultiStem In Ischemic Stroke, Signs Memorandum Of Understanding For Global ARDS License With Healios; Includes $1.5M To $4.5M Near Term Payments Plus Up To $150M In Milestones

By Benzinga Newsdesk
October 10, 8:37 AM
The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestonesAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care

ATHX